Most if not all of the liposomal products I see on the market utilize sublingual delivery for the reason of bypassing the stomach acids that would destroy the liposomal shell. It's one thing for them to claim that it is shelf stable vs another to claim their liposomal products would survive stomach acids intact and still be able to cross the blood brain barrier. I don't see any proof of the company conducting studies showing this.
On a side note, I am investor in MNKD which has developed an inhaleable technosphere nanoparticle delivery system for insulin. They have had FDA approval for a couple of years and are still struggling to gain traction in having endocrinologists switch diabetics from multiple mealtime injections or an insulin pump, even though the nanoparticle delivery system has shown improvement in hemoglobin A1C levels and less hypoglycemic fluctuations from both injections and the pump. MNKD has already licensed out their delivery system for one drug, and it could eventually be a delivery system for neutraceuticals too.
As a physician I presently use a liposomal glutathione product. It is great for brain related problems. Could MILV develop something like that and prove that its nanoparticles delivered the glutathione across the blood brain barrier in a superior fashion to other glutathione products? MNKD could do the same but I think they are focused on the pharma end.
I hope MILV makes it big but I am feeling a little skeptical.
News 
Market Data 
Discover 
